The Proteomics Core Facility makes advanced mass spectrometry instruments, expertise, and methods for protein analysis available to the Case Comprehensive Cancer Center (Case CCC) community. The Core includes two laboratory sites, one on the CWRU campus and one the CCF campus, with a current total of 6,000 sq ft of laboratory space. The Core is directed by Dr. Mark Chance and has a staff of approximately 20 individuals including scientists specializing in mass spectrometry, protein chemistry, instrument engineering, and bioinformatics. A total of 8 mass spectrometry systems are housed in the laboratories, including electrospray and Maldi, and ion trap, ToF, QTof, and FTMS systems. The services that are offered to the Case CCC community are wide-ranging;from a drop-off service for protein identification, to collaborative services for the detection and characterization of post-translation modifications, quantitative proteomics, and protein structural analyses to open instrument access for trained users. Members have used mass spectrometry from the Core, to reveal that the reversible dimethylation on K140 by histone-modifying enzymes occurs only when it is part of a promoter-bound complex. Other members have utilized the Core to identify DNMT1-associated proteins including HAUSP from a series of pull down experiments. In particular, in-solution samples generated from pull down experiments were analyzed by tandem MS. The Core has provided services for Cancer Center members from 7 of the 8 Scientific Research Programs.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research Involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-24
Application #
8765393
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
24
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Gromovsky, Anthony D; Schugar, Rebecca C; Brown, Amanda L et al. (2018) ?-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 38:218-231
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376
Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237
Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Liu, Xia; Taftaf, Rokana; Kawaguchi, Madoka et al. (2018) Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. Cancer Discov :
Belur Nagaraj, Anil; Joseph, Peronne; Kovalenko, Olga et al. (2018) Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer. Gynecol Oncol 151:525-532
Li, Jiayang; Gresham, Kenneth S; Mamidi, Ranganath et al. (2018) Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy. Int J Cardiol 273:168-176
Enane, Francis O; Saunthararajah, Yogen; Korc, Murray (2018) Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis 9:912

Showing the most recent 10 out of 1227 publications